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Abstract
Background: Soft tissue sarcomas (STSs) are rare malignant tumors of embryo-
genic mesoderm origin. Primary thoracic STSs account for a small percentage of all
STSs and limited published information is available. This study aimed to identify the
prognostic factors for thoracic STSs and evaluate the disease’s clinical outcomes.
Methods: The medical records of 109 patients with thoracic STSs who were treated
between 2003 and 2013 were retrospectively reviewed. Patients’ survival rates were
analyzed and potential prognostic factors evaluated.
Results: The median follow-up period was 29 months (range: 1–121 months). STSs
were most frequently localized on the chest wall (n = 42; 38.5%) and lungs (n = 42;
38.5%). The most common histological types were malignant fibrous histiocytoma
(n = 23; 21.1%), liposarcoma (n = 17; 15.6%), and leiomyosarcoma (n = 16; 14.7%).
The median survival time of all patients was 40.3 months (95% confidence interval,
14.22–66.37 months), with one and five-year survival rates of 93.4% and 63.5%,
respectively. Univariate analysis of all groups revealed that metastatic stage,
unresectability, tumor diameter of >10 cm, tumor location other than the chest wall,
and grade 3 diseases were predictable of poor survival. However, only grade 3 dis-
eases and tumor location other than the chest wall were confirmed by multivariate
analysis as poor prognostic factors.
Conclusions: Primary thoracic STSs are rarely seen malignant tumors. Our results
indicated that patients with low-grade tumors and those localized on the chest wall
often experienced better survival outcomes.
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Introduction
Soft tissue sarcomas (STSs) are rare malignant tumors of
embryogenic mesoderm origin.1 They account for less than
1% of all human malignancies.1 Approximately 60% of STSs
are localized on the extremities with the remaining com-
monly found in the gastrointestinal, retroperitoneal, head,
and neck regions.2 Thoracic STSs account for a small percent-
age (3–8%) of STSs3,4 with tumors often found in the lungs,
mediastinum, pleura, pericardium, heart, and chest walls.5
STS is a heterogenous disease with more than 60 histologi-
cal types.6 Malignant fibrous histiocytomas and liposarcomas
are the most commonly observed STSs of the extremities,
whereas the frequency of thoracic STS histological types
varies depending on tumor location,2 such as fibrosarcomas
and leiomyosarcomas in the lungs, angiosarcomas in the
heart, and malignant fibrous histiocytomas on the chest
wall.7–10
Multimodality therapy, including surgery, radiotherapy,
and chemotherapy, is commonly used for the treatment of
STSs.2,11–13 Of these, surgery is the most important compo-
nent. Clinical parameters such as patients’ age, Eastern Coop-
erative Oncology Group (ECOG) performance status, tumor
histology, and tumor grade are often considered when other
treatment modalities are elected. Although the surgical treat-
ment outcomes of thoracic STSs have been analyzed in
several published studies, such analyses are not available for
any other treatment modalities.
Furthermore, although the prognostic factors for overall
STS patient survival have been thoroughly analyzed,11,14 only
one study thus far has specifically examined those in primary
thoracic STSs.15 Otherwise, most published reports have
focused on surgical or radiological studies of thoracic STS
retrospective case series or case reports.16–18
The present study aimed to determine the clinico-
pathological features, survival rates, and prognostic factors of
patients with primary thoracic STSs treated at major hospi-
tals in Turkey.
Materials and methods
Study design
The present study was designed as a retrospective analysis of a
primary thoracic STS patient cohort.
Methods
The Executive Committee of Anatolian Society of Medical
Oncology approved this study. We collected data from
patients with primary STSs treated at 15 different medical
oncology centers in Turkey. Data collection began in Febru-
ary 2012. Information on patients’ age, gender, tumor size,
location, and the presence of primary tumor and metastatic
site were retrieved from their medical records. The 2002
World Health Organization criteria were used for histopatho-
logical diagnosis of all patients,19 and the Fédération
Nationale des Centres de Lutte Contre le Cancer system was
used for tumor grading.20 In addition, treatment modalities
(cytotoxic agents, chemotherapy regimen, surgery, and radio-
therapy), clinical outcomes, time to disease progression, mor-
tality rates, and the length of follow-up periods were recorded
until the last visit in October 2013.
The inclusion criteria were as follows: (i) STS histology; (ii)
the primary tumor site being within the thoracic region,
including the chest wall, lungs, pleura, mediastinum, pericar-
dium, and heart; and (iii) patient’s age of >18 years. The
exclusion criteria included: (i) skeletal sarcoma (excluding
extra-skeletal Ewing sarcoma and extra-skeletal chondrosar-
coma); (ii) desmoid tumor; and (iii) dermatofibrosarcoma
protuberans.
Statistical analysis
Data were analyzed using the Statistical Package for the
Social Sciences (SPSS) version 15.0 for Windows (SPSS Inc.,
Chicago, IL). Overall survival (OS) was calculated from the
surgery time or the time of diagnosis to death or the last day
of the follow-up period. The Kaplan-Meier method was used
for OS analysis. For the comparison of survival rate differ-
ences, a log-rank (Mantel-Cox) test was used for univariate
analysis and Cox-proportional hazards model for multivari-
ate analysis. A P-value of <0.05 was considered statistically
significant. The following factors were evaluated in the prog-
nostic factor analysis: gender (male or female); age (<50 and
≥50 years), stage (local, locally advanced, and metastatic),
tumor diameter (0–5 cm, 5–10 cm, or ≥10 cm), grade (1
and 3), resection (complete, incomplete resection, and
unresectable), ECOG performance status (0, 1, and 2), tumor
location (the chest wall, lungs, or other), adjuvant radio-
therapy (applied or not), and adjuvant chemotherapy
(applied or not).
Results
Global patient characteristics and
treatment alternatives
This study enrolled 109 patients with a male/female ratio of
1:3. Patient characteristics are summarized in Table 1. The
primary tumor was commonly located in the mediastinum
(n = 16; 14.7%), pleura (n = 5; 4.6%), intracardiac region (n =
3; 2.8%), and pericardium (n = 1; 0.9%). Malignant fibrous
histiocytoma was the most frequently observed histological
type. When separate groups were considered, malignant
fibrous histiocytoma was often found on the chest wall
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(n = 16; 38%), leiomyosarcoma in the lungs (n = 12; 28.5%),
liposarcoma in the mediastinum (n = 4; 25%), unclassified
sarcoma in the pleura (n = 2; 40%), and angiosarcoma in the
intracardiac region (n = 2; 66.6%). Synovial sarcoma was
detected in the pericardium of one patient. Ewing sarcomas
were observed in the lungs (n = 9) and mediastinum (n = 2).
Additionally, chondrosarcomas were detected in the lungs of
two patients.
Seventy-five patients underwent tumor resection, mostly
complete resection with only 11% incomplete resection (R1
resection). The characteristics of these surgical patients
are listed in Table 1. Adjuvant chemotherapy (n = 46) or
radiotherapy (n = 39) was provided to all surgical patients.
The adjuvant chemotherapy regimens included ifosfamide-
doxorubicin (n = 32), vincristine-adriamycin-cyclopho-
sphamide (VAC) and ifosfamide-etoposide (IE) combination
(n = 7), cisplatin and doxorubicin combination (n = 4), and
VAC (n = 3).
Palliative chemotherapy was provided to 58 patients
with metastatic diseases at baseline or progression. The
administered regimens included IE combination,
gemcitabine-docetaxel combination, cisplatin-etoposide
combination, cyclophosphamide, vincristine, doxorubicin,
and dacarbazine (CYVADIC), and paclitaxel.
Survival outcomes
The median follow-up period was 29 months (range, 1–121
months). At the time of the present analysis, 51 patients had
died. The median OS of all patients was 40.3 months (95%
confidence interval [CI], 14.2–66.3 months) (Fig 1) with one
and five-year survival rates of 93.4% and 63.5%, respectively.
The median OS of patients undergoing resection was 53.6
months (95% CI, 16–91.3 months) with one and five-year
survival rates of 91.5% and 46.5%, respectively (Fig 2).
Patients with tumors located on the chest wall tended to expe-
rience a better OS (median, 78.2 months) than those with dis-
eases in the lungs (median, 20.6 months) and other locations
(median, 15.4 months) (P = 0.022) (Fig 3).
Analysis of potential prognostics
The factors included in the univariate and multivariate analy-
ses of surgical patients’ survival rates are listed in Table 2.
Table 1 Patient characteristics
All patients
(n = 109)
Surgery group
(n = 75)
Median age 46 (18–85) 46 (19–85)
Gender Male 62 (56.9%) 43 (57.3%)
Female 47 (43.1%) 32 (42.7%)
Primary
tumor site
Chest wall 42 (38.5%) 36 (48%)
Lung 42 (38.5%) 25 (33.3%)
Others† 25 (23%) 14 (18.7%)
Histological
type
Malignant fibrous
histiocytoma
23 (21.2%) 20 (26.7%)
Liposarcoma 17 (15.6%) 12 (16%)
Leiomyosarcoma 16 (14.7%) 10 (13.3%)
Unclassified 14 (12.8%) 10 (13.3%)
Ewing sarcoma 11 (10.1%) 6 (8%)
Synovial sarcoma 10 (9.1%) 6 (8%)
Fibrosarcoma 6 (5.5%) 4 (5.3%)
Rare types 12 (11%)‡ 7 (9.4%)
Tumor
diameter
<5 cm 20 (18.3%) 17 (22.7%)
5–10 cm 45 (41.3%) 37 (49.3%)
≥10 cm 19 (17.4%) 18 (24%)
Unknown 25 (23%) 3 (4%)
Grade 1 33 (30.3%) 26 (34.7%)
2 4 (3.7%) 1 (1.3%)
3 54 (49.5%) 37 (49.3%)
Unknown 18 (16.5%) 11 (14.7%)
Stage at
diagnosis
Local 57 (56.1%) 54 (72%)
Locally advanced 29 (22.8%) 21 (28%)
Metastatic 23 (21.1%)
Surgery Complete resection 63 (57.8%) 63 (84%)
Incomplete resection§ 12 (11%) 12 (16%)
Unresectable 34 (31.2%)
ECOG 0 27 (24.8%) 23 (30.6%)
1 58 (53.2%) 41 (53.3%)
2 24 (22%) 11 (16.1%)
ECOG, Eastern Cooperative Oncology Group performance status.
†Other, mediastinal, pleural, pericardial, or cardiac locations; ‡Rhabdo-
myosarcoma (3), angiosarcoma (2), hemangiopericytoma (2), chondro-
sarcoma (2), spindle cell (2), alveolar soft sarcoma (1), epiteloid
sarcoma (1), giant cell sarcoma (1); §R1 resection.
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Figure 1 Mean survival of all groups. , Survival Function; ,
Censored.
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Univariate analysis revealed that the absence of adjuvant che-
motherapy, tumor diameter of >10 cm, tumor location other
than the chest wall, and the presence of a grade 3 tumor were
poor prognostic factors. These four factors were included in
the subsequent multivariate analysis, which confirmed grade
3 tumors and tumor location other than the chest wall as poor
prognostic factors. Similarly, the univariate and multivariate
analyses of all patients’ survival rates are summarized in
Table 3. The univariate analysis identified metastatic stage,
unresectability, tumor diameter of >10 cm, tumor location
other than the chest wall, and the presence of a grade 3 tumor
as poor prognostic factors, whereas the multivariate analysis
subsequently confirmed the prognostic value of grade 3
tumors and tumor locations other than the chest wall.
Discussion
The present study aimed to define the clinical characteristics,
treatment alternatives, and prognostic factors for thoracic
STSs using data from multiple institutes in Turkey. The inci-
dences of both STSs and thoracic STSs peaked at 50 years of
age with a male dominancy. In our series, the median patient
age was 46 years, and there were slightly more male than
female patients, which is comparable to other published STS
and thoracic STS series.2,15,21
Malignant fibrous histiocytoma is the most common STS21
and thoracic STS type, but other histological types can also be
observed at other thoracic locations.10 In our series, angiosar-
comas were frequently detected in the cardiac region, whereas
Table 2 Univariate and multivariate analyses of surgical patients’ survival rates (n = 75)
Variable
Univariate analysis Multivariate analysis
P-value HR (95% CI) P-value
Gender (male vs. female) 0.98
Age (<50 years, ≥50 years) 0.39
Stage (local, locally advanced) 0.67
Tumor diameter (0–5 cm, 5–10 cm, ≥10 cm) 0.003
Grade (1 vs. 3) <0.001 27.6 (6.8–112.2) <0.001
Resection (complete, incomplete) 0.09
Tumor location (chest wall, lung, other) 0.02 4.63 (1.57–13.7) 0.006
Adjuvant radiotherapy (present, absent) 0.38
Adjuvant chemotherapy (present, absent) 0.01
CI, confidence interval; HR, hazard ratio.
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Figure 2 Mean survival of resected patients. , Survival Function; ,
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Figure 3 Mean survival of primary site. , Lung; , Other; ,
Chest Wall; , Lung-censored; , Other-censored; , Chest
Wall-censored.
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liposarcomas were observed more often in the mediastinum.
Our findings are in agreement with those previously reported
on these two locations.9,22 Leiomyosarcoma and fibrosarcoma
are commonly reported for lung STSs,7,8 which was also the
case in our study. However Pieper et al. reported Ewing
sarcoma as the most commonly detected STS in the lungs
with extra-osseous tumors found in the broncho-pulmonary
region.23
The survival rates in primary thoracic STS patients are
lower than those with STSs of the extremities with reported
five-year survival rates for the two diseases being 56–79% and
>75%, respectively.15,16,24–27 In our study, the five-year survival
rate and median survival time were 65% and 57 months,
respectively, which was similar to the results of previously
published thoracic STS series.
Similar prognostic factors have been assumed to affect
both patients with resected thoracic STS and those with dis-
eases of the extremities. However, such an assumption is of
limited value owing to the lower incidence of primary tho-
racic STS. Pisters et al. studied 1041 patients with STS of the
extremities and found positive histological tumor margins,
larger tumor size, and higher tumor grade to be associated
with higher mortality rates.26 On the other hand, Duranti
et al. evaluated 337 patients with resected thoracic STSs and
reported that grade 3 tumors, pulmonary and mediastinal
STS, and R1 resection were more risky than grade 1 tumors
(1.89 fold), thoracic wall STS (1.6 and 1.9 fold), and R0 resec-
tion (1.9 fold), respectively.15 Furthermore, McMillan et al.
reported that tumor grade was the most important determi-
nant of survival and recurrence pattern in patients with tho-
racic wall STSs,10 whereas Gross et al. identified tumor grade
and diameter as the most important prognostic factors for
survival in patients with chest wall STSs. In our study, among
all patients with resected thoracic STSs, the best prognosis
was noted in those with grade 1 chest wall STSs, which is com-
parable to the results published by Duranti et al. that had the
largest patient cohort to date.
Additionally,we also evaluated adjuvant treatment modali-
ties in patients with resected thoracic STS. Adjuvant chemo-
therapy, but not radiotherapy, was found to significantly
increase survival rates. Alkis et al. also obtained similar out-
comes in their study.2 Radiotherapy has been shown to
decrease local recurrence rate without contributing to
improved survival in STS patients,as confirmed in our study.12
However, to our knowledge, no study on the prognostic
factors for STS patient survival is available. Meanwhile,
resectability has emerged as an important prognostic factor
in thoracic STS, as well as all other types of STS.28 Other prog-
nostic factors, such as tumor grade, diameter, and stage were
similar to those detected in previous large STS series.2,4,20,21,26
However, among patients with resectable tumors, thoracic
STS patients might have better prognostic characteristics.
This retrospective study has many inevitable limitations.
Selection bias might have existed and patients from certain
major medical centers were enrolled. Additionally, treatment
modalities might differ with time and among clinics.
Conclusion
In conclusion, thoracic STS is a rare malignancy with diverse
histological types according to the primary tumor location.
The survival time of thoracic STS patients is apparently
shorter than that of extremity STS patients. Adjuvant chemo-
therapy might be useful for patients with resectable tumors,
whereas adjuvant radiotherapy was found to have no effect on
survival. Although the prognostic factors for thoracic STS
patient survival were similar to those of extremity STS, tho-
racic tumor location appeared to be another important factor
affecting survival.
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